Merck & Co. will add 100 new jobs as part of an expansion project at its manufacturing campus in Carlow, Ireland.
News of the increased head count comes as the company, known as MSD outside the U.S. and Canada, begins construction of a new facility at the site that will be focused on its oncology biologics, the company said.
Currently, about 530 employees work at the plant, which opened in 2008 and was the first vaccine manufacturing operation for the company outside of the U.S.
“Our site has become integral to MSD’s global manufacturing operations, continuously punching above our weight to drive innovation to make a positive impact for people and patients, from MSD Carlow to the world,” Marie Martin, the Carlow site lead, said in a statement.
Since opening operations in Carlow more than 14 years ago, MSD has continually beefed up its Irish presence. In 2017, the company said it would spend more than $310 million over three years to expand operations at its Brinny plant, which helps produce its blockbuster Keytruda immuno-oncology drug, along with the Carlow facility.